Arch Therapeutics, Inc.

OTCPK:ARTH Stock Report

Market Cap: US$912.0k

Arch Therapeutics Management

Management criteria checks 2/4

Arch Therapeutics' CEO is Terrence Norchi, appointed in Jan 2006, has a tenure of 18.92 years. total yearly compensation is $491.00K, comprised of 91.8% salary and 8.2% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $3.08K. The average tenure of the management team and the board of directors is 3.6 years and 1.9 years respectively.

Key information

Terrence Norchi

Chief executive officer

US$491.0k

Total compensation

CEO salary percentage91.8%
CEO tenure18.9yrs
CEO ownership0.3%
Management average tenure3.6yrs
Board average tenure1.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Terrence Norchi's remuneration changed compared to Arch Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023n/an/a

-US$8m

Sep 30 2023US$491kUS$451k

-US$7m

Jun 30 2023n/an/a

-US$6m

Mar 31 2023n/an/a

-US$6m

Dec 31 2022n/an/a

-US$6m

Sep 30 2022US$451kUS$451k

-US$5m

Jun 30 2022n/an/a

-US$5m

Mar 31 2022n/an/a

-US$6m

Dec 31 2021n/an/a

-US$7m

Sep 30 2021US$635kUS$451k

-US$6m

Jun 30 2021n/an/a

-US$6m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020n/an/a

-US$4m

Sep 30 2020US$698kUS$438k

-US$5m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019n/an/a

-US$4m

Sep 30 2019US$429kUS$429k

-US$5m

Jun 30 2019n/an/a

-US$5m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018n/an/a

-US$8m

Sep 30 2018US$829kUS$425k

-US$5m

Compensation vs Market: Terrence's total compensation ($USD491.00K) is about average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Terrence's compensation has increased whilst the company is unprofitable.


CEO

Terrence Norchi (59 yo)

18.9yrs

Tenure

US$491,000

Compensation

Dr. Terrence W. Norchi, M.D., serves as Chairman of the Board at Arch Therapeutics, Inc. since July 19, 2018. He is the Co-Founder of Arch Therapeutics, Inc. and has been its Chief Executive Officer and Pr...


Leadership Team

NamePositionTenureCompensationOwnership
Terrence Norchi
Co-Founder18.9yrsUS$491.00k0.34%
$ 3.1k
Michael Abrams
CFO & Treasurer3.6yrsUS$354.16k0.22%
$ 2.0k
Rutledge Ellis-Behnke
Co-Founder & Scientific Advisorno datano datano data
Shawn Carlson
Vice President of Salesless than a yearno datano data

3.6yrs

Average Tenure

Experienced Management: ARTH's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Terrence Norchi
Co-Founder11.7yrsUS$491.00k0.34%
$ 3.1k
Guy Fish
Independent Director3yrsUS$8.10k0%
$ 0
Matthew Garoufalis
Member of Medical Advisory Board1.9yrsno datano data
John Lantis
Member of Medical Advisory Board1.9yrsno datano data
Gregory Bohn
Member of Medical Advisory Board1.9yrsno datano data
Terry Treadwell
Member of Medical Advisory Board1.9yrsno datano data
Brock Liden
Member of Medical Advisory Board1.9yrsno datano data
William Austen
Clinical Advisorno datano datano data

1.9yrs

Average Tenure

64yo

Average Age

Experienced Board: ARTH's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 02:07
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arch Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuH.C. Wainwright & Co.
Michael HigginsLadenburg Thalmann & Company
Raghuram SelvarajuRodman & Renshaw, LLC